Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Pretransplatation PET as Major Prognostic Discriminant in IGEV (ifosfamide, gemcitabine, vinorelbine and prednisone) Treated Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL).

Rita Mazza, MD, Stefano Luminari, Massimo Magagnoli, MD, Michele Spina, MD, Teodoro Chisesi, MD, Antonio Pinto, MD, Massimo Federico, MD, Antonella Anastasia, MD, Arturo Chiti, MD, Mariagrazia Michieli, MD, Francesco Angrilli, MD, Luca Castagna, Giampaolo Marcacci, Laura Giordano, PhD, Umberto Tirelli, MD, Armando Santoro, Monica Balzarotti

Blood (2009) 114 (22): 3707.

https://doi.org/10.1182/blood.V114.22.3707.3707

Published: 2009

Journal Articles

Conventional Chemotherapy Followed by Consolidation with Autologous Hematopoietic Transplantation Vs Chemotherapy Alone in HIV+ Patients with Large B Cell Lymphoma (LBCL) in First Complete Remission (CR). A Retrospective Analysis On Behalf of the EBMT Lymphoma Working Party and the GESIDA/PETHEMA Registry of HIV+ Patients with Non-Hodgkin's Lymphoma (NHL).

Pascual Balsalobre, BN, Juan Berenguer, MD, PhD, Pilar Miralles, MD, PhD, David Serrano, MD, Josep-Maria Ribera, MD, PhD, Carmen Canals, MD, PhD, Marisa Montes, MD, Mariagrazia Michieli, MD, Eulalia Valencia, MD, Anne Rosselet, MD, Francisco Rodríguez-Arrondo, MD, Philippe Genet, MD, Maria J Galindo, MD, Augustin Ferrant, MD, PhD, Vicente Pintado, MD, Jose M Bellon, Anna Sureda, MD, PhD, Jose L. Diez-Martin, MD, PhD

Blood (2009) 114 (22): 4355.

https://doi.org/10.1182/blood.V114.22.4355.4355

Published: 2009

Journal Articles

High Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation as Salvage Therapy for HIV-Associated Lymphoma: Result of the GICAT Study.

Alessandro Re, MD, Mariagrazia Michieli, MD, Chiara Cattaneo, MD, Maurizio Rupolo, MD, Salvatore Casari, MD, Michele Spina, MD, Bernardino Allione, MD, Camillo Almici, MD, Piero Ferremi, MD, Luciano Abruzzese, MD, Cecilia Simonelli, MD, Rosa Manuele, MD, Alessandro Levis, MD, Giampiero Carosi, MD, Umberto Tirelli, MD, Giuseppe Rossi, MD

Blood (2007) 110 (11): 23.

https://doi.org/10.1182/blood.V110.11.23.23

Published: 2007

Journal Articles

Factors Affecting Outcome of Patients with Refractory/Relapsed Hodgkin’s Disease (HD) Treated with IGEV Chemotherapy (CT) and High Dose Consolidation Therapy (HDT) with Stem Cell Rescue.

Monica Balzarotti, MD, Michele Spina, MD, Massimo Magagnoli, MD, Teodoro Chisesi, MD, Antonello Pinto, MD, Luca Castagna, MD, Monica Demarco, MD, Mariagrazia Michieli, MD, Andrea Nozza, MD, Umberto Tirelli, MD, Armando Santoro, MD

Blood (2005) 106 (11): 2091.

https://doi.org/10.1182/blood.V106.11.2091.2091

Published: 2005

Journal Articles

Tymic Output after Autologous Bone Marrow Transplantation (ASCT) HIV-Related Lymphoma.

Cecilia Simonelli, MD, Michele Spina, MD, Chiara Pratesi, ScD, Rosamaria Tedeschi, ScD, Maurizio Rupolo, MD, Maria Teresa Bortolin, ScD, Stefania Zanussi, ScD, Mariagrazia Michieli, MD, Paolo De Paoli, MD, Umberto Tirelli, MD

Blood (2005) 106 (11): 2933.

https://doi.org/10.1182/blood.V106.11.2933.2933

Published: 2005

Journal Articles

High Dose Therapy (HDCT) with Autologous Stem Cell Transplantation (ASCT) for Non-Hodgkin Lymphoma in the Elderly: Feasibility of a Patient-Tailored Treatment Plan.

Maurizio Rupolo, MD, Mariagrazia Michieli, MD, Michele Spina, MD, Daniele Bernardi, MD, Massimiliano Berretta, MD, Annalisa Giacalone, Psic, Umberto Tirelli, MD

Blood (2004) 104 (11): 5216.

https://doi.org/10.1182/blood.V104.11.5216.5216

Published: 2004

Journal Articles

R-DHAOX as Salvage Regimen in Patients (pts) with Relapsed/Resistant Non-Hodgkin[spos]s Lymphoma (NHL).

Maurizio Rupolo, MD, Michele Spina, MD, Mariagrazia Michieli, MD, Massimiliano Berretta, MD, Luciano Abbruzzese, MD, Mario Mazzucato, MD, Valter Gattei, MD, Umberto Tirelli, MD

Blood (2004) 104 (11): 1323.

https://doi.org/10.1182/blood.V104.11.1323.1323

Published: 2004

Journal Articles

Ann Arbor Stage Is the Most Important Predictor of Survival for Refractory and Relapsed HIV-Associated Lymphoma Enrolled in a Program of High Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation.

Alessandro Re, MD, Chiara Cattaneo, MD, MariaGrazia Michieli, MD, Salvatore Casari, MD, Michele Spina, MD, Maurizio Rupolo, MD, Bernardino Allione, MD, Piero Ferremi, MD, Arnalda Lanfranchi, PhD, Mauro Mazzuccato, MD, Gianpiero Carosi, MD, Umberto Tirelli, MD, Giuseppe Rossi, MD

Blood (2004) 104 (11): 893.

https://doi.org/10.1182/blood.V104.11.893.893

Published: 2004

NARROW

Pretransplatation PET as Major Prognostic Discriminant in IGEV (ifosfamide, gemcitabine, vinorelbine and prednisone) Treated Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL).

High Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation as Salvage Therapy for HIV-Associated Lymphoma: Result of the GICAT Study.

Factors Affecting Outcome of Patients with Refractory/Relapsed Hodgkin’s Disease (HD) Treated with IGEV Chemotherapy (CT) and High Dose Consolidation Therapy (HDT) with Stem Cell Rescue.

Tymic Output after Autologous Bone Marrow Transplantation (ASCT) HIV-Related Lymphoma.

High Dose Therapy (HDCT) with Autologous Stem Cell Transplantation (ASCT) for Non-Hodgkin Lymphoma in the Elderly: Feasibility of a Patient-Tailored Treatment Plan.

R-DHAOX as Salvage Regimen in Patients (pts) with Relapsed/Resistant Non-Hodgkin[spos]s Lymphoma (NHL).

Ann Arbor Stage Is the Most Important Predictor of Survival for Refractory and Relapsed HIV-Associated Lymphoma Enrolled in a Program of High Dose Therapy and Autologous Peripheral Blood Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only